{"id":25165,"date":"2023-09-15T11:58:00","date_gmt":"2023-09-15T16:58:00","guid":{"rendered":"https:\/\/myeloma.ca\/?p=25165"},"modified":"2025-08-19T08:28:09","modified_gmt":"2025-08-19T13:28:09","slug":"mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/","title":{"rendered":"M\u00e9canismes d\u2019\u00e9chappement de l\u2019antig\u00e8ne BCMA ou immunoth\u00e9rapies ciblant le GPRC5D pour traiter le my\u00e9lome multiple"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">La perte de la cible de l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) est consid\u00e9r\u00e9e comme un \u00e9v\u00e9nement rare qui induit une r\u00e9sistance aux th\u00e9rapies par transfert de lymphocytes T porteurs de r\u00e9cepteurs antig\u00e9niques chim\u00e9riques (th\u00e9rapie cellulaire CAR-T) qui cible l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) ou \u00e0 base d\u2019anticorps bisp\u00e9cifique ciblant les cellules T (TCE). Selon de r\u00e9centes donn\u00e9es, une r\u00e9gulation \u00e0 la baisse du membre D du groupe 5 de la famille C des r\u00e9cepteurs coupl\u00e9s aux prot\u00e9ines G (GPRC5D) survient souvent au moment de la rechute \u00e0 la suite d\u2019une th\u00e9rapie par CAR-T ciblant le GPRC5D. Pour examiner les facteurs intrins\u00e8ques de la tumeur qui favorisent l\u2019\u00e9chappement de l\u2019antig\u00e8ne chez les patients atteints d\u2019un my\u00e9lome, nous avons proc\u00e9d\u00e9 \u00e0 un profilage g\u00e9nomique monocellulaire et multicellulaire et \u00e0 une analyse des variations du nombre de copies chez 30 patients ayant re\u00e7u une th\u00e9rapie CAR-T\/TCE ciblant l\u2019antig\u00e8ne BCMA et\/ou GPRC5D.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pour en savoir plus, <a href=\"https:\/\/www.nature.com\/articles\/s41591-023-02491-5\" target=\"_blank\" rel=\"noopener\" title=\"\">cliquez ici<\/a>. (en anglais seulement)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La perte de la cible de l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) est consid\u00e9r\u00e9e comme un \u00e9v\u00e9nement rare qui induit une r\u00e9sistance aux th\u00e9rapies par transfert de lymphocytes T porteurs de r\u00e9cepteurs antig\u00e9niques chim\u00e9riques (th\u00e9rapie cellulaire CAR-T) qui cible l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) ou \u00e0 base d\u2019anticorps bisp\u00e9cifique ciblant les cellules [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[53,58],"tags":[],"class_list":["post-25165","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-nouvelles-de-myelome-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"La perte de la cible de l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) est consid\u00e9r\u00e9e comme un \u00e9v\u00e9nement rare qui induit une r\u00e9sistance aux th\u00e9rapies par transfert de lymphocytes T porteurs de r\u00e9cepteurs antig\u00e9niques chim\u00e9riques (th\u00e9rapie cellulaire CAR-T) qui cible l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) ou \u00e0 base d\u2019anticorps bisp\u00e9cifique ciblant les cellules\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"M\u00e9canismes d\u2019\u00e9chappement de l\u2019antig\u00e8ne BCMA ou immunoth\u00e9rapies ciblant le GPRC5D pour traiter le my\u00e9lome multiple | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"La perte de la cible de l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) est consid\u00e9r\u00e9e comme un \u00e9v\u00e9nement rare qui induit une r\u00e9sistance aux th\u00e9rapies par transfert de lymphocytes T porteurs de r\u00e9cepteurs antig\u00e9niques chim\u00e9riques (th\u00e9rapie cellulaire CAR-T) qui cible l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) ou \u00e0 base d\u2019anticorps bisp\u00e9cifique ciblant les cellules\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2023-09-15T16:58:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:09+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"M\u00e9canismes d\u2019\u00e9chappement de l\u2019antig\u00e8ne BCMA ou immunoth\u00e9rapies ciblant le GPRC5D pour traiter le my\u00e9lome multiple | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"La perte de la cible de l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) est consid\u00e9r\u00e9e comme un \u00e9v\u00e9nement rare qui induit une r\u00e9sistance aux th\u00e9rapies par transfert de lymphocytes T porteurs de r\u00e9cepteurs antig\u00e9niques chim\u00e9riques (th\u00e9rapie cellulaire CAR-T) qui cible l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) ou \u00e0 base d\u2019anticorps bisp\u00e9cifique ciblant les cellules\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/09\\\/15\\\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\\\/#blogposting\",\"name\":\"M\\u00e9canismes d\\u2019\\u00e9chappement de l\\u2019antig\\u00e8ne BCMA ou immunoth\\u00e9rapies ciblant le GPRC5D pour traiter le my\\u00e9lome multiple | My\\u00e9lome Canada\",\"headline\":\"M\\u00e9canismes d\\u2019\\u00e9chappement de l\\u2019antig\\u00e8ne BCMA ou immunoth\\u00e9rapies ciblant le GPRC5D pour traiter le my\\u00e9lome multiple\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2023-09-15T11:58:00-05:00\",\"dateModified\":\"2025-08-19T08:28:09-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/09\\\/15\\\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/09\\\/15\\\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement, Nouvelles de My\\u00e9lome Canada\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/09\\\/15\\\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"position\":2,\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/nouvelles-de-myelome-canada\\\/#listItem\",\"name\":\"Nouvelles de My\\u00e9lome Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/nouvelles-de-myelome-canada\\\/#listItem\",\"position\":3,\"name\":\"Nouvelles de My\\u00e9lome Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/nouvelles-de-myelome-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/09\\\/15\\\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\\\/#listItem\",\"name\":\"M\\u00e9canismes d\\u2019\\u00e9chappement de l\\u2019antig\\u00e8ne BCMA ou immunoth\\u00e9rapies ciblant le GPRC5D pour traiter le my\\u00e9lome multiple\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/09\\\/15\\\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\\\/#listItem\",\"position\":4,\"name\":\"M\\u00e9canismes d\\u2019\\u00e9chappement de l\\u2019antig\\u00e8ne BCMA ou immunoth\\u00e9rapies ciblant le GPRC5D pour traiter le my\\u00e9lome multiple\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/nouvelles-de-myelome-canada\\\/#listItem\",\"name\":\"Nouvelles de My\\u00e9lome Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/09\\\/15\\\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/09\\\/15\\\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/09\\\/15\\\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/09\\\/15\\\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/09\\\/15\\\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\\\/\",\"name\":\"M\\u00e9canismes d\\u2019\\u00e9chappement de l\\u2019antig\\u00e8ne BCMA ou immunoth\\u00e9rapies ciblant le GPRC5D pour traiter le my\\u00e9lome multiple | My\\u00e9lome Canada\",\"description\":\"La perte de la cible de l\\u2019antig\\u00e8ne de maturation des lymphocytes B (BCMA) est consid\\u00e9r\\u00e9e comme un \\u00e9v\\u00e9nement rare qui induit une r\\u00e9sistance aux th\\u00e9rapies par transfert de lymphocytes T porteurs de r\\u00e9cepteurs antig\\u00e9niques chim\\u00e9riques (th\\u00e9rapie cellulaire CAR-T) qui cible l\\u2019antig\\u00e8ne de maturation des lymphocytes B (BCMA) ou \\u00e0 base d\\u2019anticorps bisp\\u00e9cifique ciblant les cellules\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/09\\\/15\\\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2023-09-15T11:58:00-05:00\",\"dateModified\":\"2025-08-19T08:28:09-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"M\u00e9canismes d\u2019\u00e9chappement de l\u2019antig\u00e8ne BCMA ou immunoth\u00e9rapies ciblant le GPRC5D pour traiter le my\u00e9lome multiple | My\u00e9lome Canada","description":"La perte de la cible de l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) est consid\u00e9r\u00e9e comme un \u00e9v\u00e9nement rare qui induit une r\u00e9sistance aux th\u00e9rapies par transfert de lymphocytes T porteurs de r\u00e9cepteurs antig\u00e9niques chim\u00e9riques (th\u00e9rapie cellulaire CAR-T) qui cible l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) ou \u00e0 base d\u2019anticorps bisp\u00e9cifique ciblant les cellules","canonical_url":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/#blogposting","name":"M\u00e9canismes d\u2019\u00e9chappement de l\u2019antig\u00e8ne BCMA ou immunoth\u00e9rapies ciblant le GPRC5D pour traiter le my\u00e9lome multiple | My\u00e9lome Canada","headline":"M\u00e9canismes d\u2019\u00e9chappement de l\u2019antig\u00e8ne BCMA ou immunoth\u00e9rapies ciblant le GPRC5D pour traiter le my\u00e9lome multiple","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2023-09-15T11:58:00-05:00","dateModified":"2025-08-19T08:28:09-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/#webpage"},"articleSection":"Actualit\u00e9s et \u00e9v\u00e9nement, Nouvelles de My\u00e9lome Canada"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","position":2,"name":"Actualit\u00e9s et \u00e9v\u00e9nement","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/nouvelles-de-myelome-canada\/#listItem","name":"Nouvelles de My\u00e9lome Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/nouvelles-de-myelome-canada\/#listItem","position":3,"name":"Nouvelles de My\u00e9lome Canada","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/nouvelles-de-myelome-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/#listItem","name":"M\u00e9canismes d\u2019\u00e9chappement de l\u2019antig\u00e8ne BCMA ou immunoth\u00e9rapies ciblant le GPRC5D pour traiter le my\u00e9lome multiple"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/#listItem","position":4,"name":"M\u00e9canismes d\u2019\u00e9chappement de l\u2019antig\u00e8ne BCMA ou immunoth\u00e9rapies ciblant le GPRC5D pour traiter le my\u00e9lome multiple","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/nouvelles-de-myelome-canada\/#listItem","name":"Nouvelles de My\u00e9lome Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/","name":"M\u00e9canismes d\u2019\u00e9chappement de l\u2019antig\u00e8ne BCMA ou immunoth\u00e9rapies ciblant le GPRC5D pour traiter le my\u00e9lome multiple | My\u00e9lome Canada","description":"La perte de la cible de l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) est consid\u00e9r\u00e9e comme un \u00e9v\u00e9nement rare qui induit une r\u00e9sistance aux th\u00e9rapies par transfert de lymphocytes T porteurs de r\u00e9cepteurs antig\u00e9niques chim\u00e9riques (th\u00e9rapie cellulaire CAR-T) qui cible l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) ou \u00e0 base d\u2019anticorps bisp\u00e9cifique ciblant les cellules","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2023-09-15T11:58:00-05:00","dateModified":"2025-08-19T08:28:09-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"M\u00e9canismes d\u2019\u00e9chappement de l\u2019antig\u00e8ne BCMA ou immunoth\u00e9rapies ciblant le GPRC5D pour traiter le my\u00e9lome multiple | My\u00e9lome Canada","og:description":"La perte de la cible de l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) est consid\u00e9r\u00e9e comme un \u00e9v\u00e9nement rare qui induit une r\u00e9sistance aux th\u00e9rapies par transfert de lymphocytes T porteurs de r\u00e9cepteurs antig\u00e9niques chim\u00e9riques (th\u00e9rapie cellulaire CAR-T) qui cible l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) ou \u00e0 base d\u2019anticorps bisp\u00e9cifique ciblant les cellules","og:url":"https:\/\/myeloma.ca\/fr\/2023\/09\/15\/mecanismes-dechappement-de-lantigene-bcma-ou-immunotherapies-ciblant-le-gprc5d-pour-traiter-le-myelome-multiple\/","article:published_time":"2023-09-15T16:58:00+00:00","article:modified_time":"2025-08-19T13:28:09+00:00","twitter:card":"summary_large_image","twitter:title":"M\u00e9canismes d\u2019\u00e9chappement de l\u2019antig\u00e8ne BCMA ou immunoth\u00e9rapies ciblant le GPRC5D pour traiter le my\u00e9lome multiple | My\u00e9lome Canada","twitter:description":"La perte de la cible de l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) est consid\u00e9r\u00e9e comme un \u00e9v\u00e9nement rare qui induit une r\u00e9sistance aux th\u00e9rapies par transfert de lymphocytes T porteurs de r\u00e9cepteurs antig\u00e9niques chim\u00e9riques (th\u00e9rapie cellulaire CAR-T) qui cible l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) ou \u00e0 base d\u2019anticorps bisp\u00e9cifique ciblant les cellules"},"aioseo_meta_data":{"post_id":"25165","title":null,"description":null,"keywords":[],"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":[],"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-12-15 17:00:38","updated":"2026-04-30 08:39:06","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/25165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=25165"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/25165\/revisions"}],"predecessor-version":[{"id":25166,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/25165\/revisions\/25166"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=25165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=25165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=25165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}